Who’s on third? Regulation of third-party genetic interpretation services

Article metrics

ABSTRACT

In recent years, third-party genetic interpretation services have emerged to help individuals understand their raw genetic data obtained from researchers, clinicians, and direct-to-consumer genetic testing companies. The objectives of these services vary but include matching users to genetic relatives, selling customized diet and fitness plans, and providing health risk assessments. As these services proliferate, concerns are being raised about their accuracy, safety, and privacy practices. Thus far, US regulatory agencies have not taken an official position with respect to third-party genetic interpretation services, which has caused uncertainty regarding whether and how they might be regulated. To clarify this area, we analyzed their potential oversight by four US agencies that generally have been active in the regulation of genetic testing services and information: the Centers for Medicare and Medicaid Services, the Food and Drug Administration, the Department of Health and Human Services’ Office of Civil Rights, and the Federal Trade Commission. We conclude that the scope of federal jurisdiction over third-party genetic interpretation services—while limited—could be appropriate at this time, subject to agency clarification and appropriate exercise of oversight.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Thorogood A, Bobe J, Prainsack B, et al. APPLaUD: access for patients and participants to individual level uninterpreted genomic data. Hum Genomics. 2018;12:7.

  2. 2.

    Nelson SC, Fullerton SM. “Bridge to the literature”? third-party genetic interpretation tools and the views of tool developers. J Genet Couns. 2018;27:770–781.

  3. 3.

    Nelson SC, Bowen DJ, Fullerton SM. Third-party genetic interpretation tools: a mixed-methods study of consumer motivation and behavior. Am J Hum Genet. 2019;105:122–131.

  4. 4.

    Wang C, Cahill TJ, Parlato A, et al. Consumer use and response to online third-party raw DNA interpretation services. Mol Genet Genomic Med. 2018;6:35–43.

  5. 5.

    Moscarello T, Murray B, Reuter CM, Demo E. Direct-to-consumer raw genetic data and third-party interpretation services: more burden than bargain? Genet Med. 2019;21:539–541.

  6. 6.

    Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med. 2018;20:1515–1521.

  7. 7.

    Allen CG, Gabriel J, Flynn M, Cunningham TN, Wang C. The impact of raw DNA availability and corresponding online interpretation services: a mixed-methods study. Transl Behav Med. 2018;8:105–112.

  8. 8.

    Badalato L, Kalokairinou L, Borry P. Third party interpretation of raw genetic data: an ethical exploration. Eur J Hum Genet. 2017;25:1189–1194.

  9. 9.

    Duranske S. This article makes you smarter! (or, regulating health and wellness claims). Am J Law Med. 2017;43:7–55.

  10. 10.

    Regalado A. How a wiki is keeping direct-to-consumer genetics alive. MIT Technol Rev. 2014. https://www.technologyreview.com/s/531461/how-a-wiki-is-keeping-direct-to-consumer-genetics-alive/. Accessed 11 March 2019.

  11. 11.

    Messner DA, Al Naber J, Koay P, et al. Barriers to clinical adoption of next generation sequencing: perspectives of a policy Delphi panel. Appl Transl Genom. 2016;10:19–24.

  12. 12.

    Future of Privacy Forum. Privacy best practices for consumer genetic testing services. 2018. https://fpf.org/wp-content/uploads/2018/07/Privacy-Best-Practices-for-Consumer-Genetic-Testing-Services-FINAL.pdf. Accessed 20 March 2019.

  13. 13.

    Regalado A. More than 26 million people have taken an at-home ancestry test. MIT Technol Rev. 2019. https://www.technologyreview.com/s/612880/more-than-26-million-people-have-taken-an-at-home-ancestry-test/. Accessed 11 March 2019.

  14. 14.

    Code of Maryland Regulations. 2019; title 10, subtitle 10.

  15. 15.

    Karow J. Consumer genomics startup Genos Research plans to let customers explore, share their data. GenomeWeb. 2016. https://www.genomeweb.com/molecular-diagnostics/consumer-genomics-startup-genos-research-plans-let-customers-explore-share#.XIFIudPwbOQ. Accessed 11 March 2019.

  16. 16.

    National Academies of Sciences, Engineering, and Medicine. Returning individual research results to participants: guidance for a new research paradigm. Washington, DC: National Academies Press; 2018.

  17. 17.

    All of Us Research Program. Operational protocol. https://allofus.nih.gov/sites/default/files/aou_core_protocol_v1.7_mar_2018.pdf. Accessed 18 March 2019.

  18. 18.

    Evans BJ. HIPAA’s individual right of access to genomic data: reconciling safety and civil rights. Am J Hum Genet. 2018;102:5–10.

  19. 19.

    US Department of Health and Human Services (HHS). Standards for privacy of individually identifiable health information. Fed Regist. 2000;65:82461–82829.

  20. 20.

    Code Fed Regulations. 2019; title 45, §164.524.

  21. 21.

    HHS. CLIA program and HIPAA Privacy Rule. Fed Regist. 2014;79:7289–7316.

  22. 22.

    Individuals’ right under HIPAA to access their health information 45 CFR § 164.524. 2016. https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/access/index.html#newlyreleasedfaqs. Accessed 28 March 2019.

  23. 23.

    Salari K, Karczewski KJ, Hudgins L, Ormond KE. Evidence that personal genome testing enhances student learning in a course on genomics and personalized medicine. PLoS ONE. 2013;8:e68853.

  24. 24.

    Weitzel KW, McDonough CW, Elsey AR, Burkley B, Cavallari LH, Johnson JA. Effect of using personal genotype data on student learning and attitudes in a pharmacogenomics course. Am J Pharm Educ. 2016;80:122.

  25. 25.

    Hazel J, Slobogin C. Who knows what, and when?: a survey of the privacy policies proffered by US direct-to-consumer genetic testing companies. Cornell J Law Public Policy. 2018;28:35–66.

  26. 26.

    Promethease. Privacy policy. https://promethease.com/privacy. Accessed 8 June 2019.

  27. 27.

    DNA.Land. Frequently asked questions. https://dna.land/faq#consent. Accessed 8 June 2019.

  28. 28.

    GEDmatch.com. Terms of service and privacy policy. 18 May 2019. https://www.gedmatch.com/tos.htm. Accessed 2019.

  29. 29.

    DNA.Land. Terms of consent. https://dna.land/consent. Accessed 8 June 2019.

  30. 30.

    Zhang S. How a tiny website became the police’s go-to genealogy database. The Atlantic. 2018. https://www.theatlantic.com/science/archive/2018/06/gedmatch-police-genealogy-database/561695/. Accessed 11 March 2019.

  31. 31.

    US Code. 2019; title 42, §263a.

  32. 32.

    Code Fed Regulations. 2019; title 42, part 493.

  33. 33.

    US National Library of Medicine. How can consumers be sure a genetic test is valid and useful? Genetics Home Reference. 2019. https://ghr.nlm.nih.gov/primer/testing/validtest. Accessed 4 Aug 2019.

  34. 34.

    Barker J. “DNA day” planned for Ravens’ game undergoes federal and state scrutiny. Baltimore Sun. 2017. http://www.baltimoresun.com/business/bs-bz-ravens-dna-day-20170918-story.html. Accessed 11 March 2019.

  35. 35.

    Javitt GH, Carner KS. Regulation of next generation sequencing. J Law Med Ethics. 2014;42 suppl 1:9–21.

  36. 36.

    Clinical Laboratory Improvement Advisory Committee (CLIAC). Summary report. 2017. https://ftp.cdc.gov/pub/CLIAC_meeting_presentations/pdf/CLIAC_Summary/cliac1117_summary.pdf. Accessed 11 March 2019.

  37. 37.

    CLIAC. Summary report. 2018. https://ftp.cdc.gov/pub/CLIAC_meeting_presentations/pdf/CLIAC_Summary/cliac0418_summary.pdf. Accessed 11 March 2019.

  38. 38.

    US Code. 2019; title 21, §321.

  39. 39.

    Code Fed Regulations. 2019; title 21, § 809.3.

  40. 40.

    HHS. Medical devices; classification/reclassification; restricted devices; analyte specific reagents. Fed Regist. 1997;62:62243–62260.

  41. 41.

    US Food and Drug Administration (FDA). Draft guidance for industry, Food and Drug Administration staff, and clinical laboratories: framework for regulatory oversight of laboratory developed tests (LDTs). 2014. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm416685.pdf. Accessed 11 March 2019.

  42. 42.

    FDA. Software as a medical device (SaMD). 2018. https://www.fda.gov/MedicalDevices/DigitalHealth/SoftwareasaMedicalDevice/default.htm. Accessed 11 March 2019.

  43. 43.

    21st Century Cures Act. Public Law No. 114–255. 2016.

  44. 44.

    FDA. Clinical and patient decision support software: draft guidance for industry and Food and Drug Administration staff. 2017. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm587819.pdf. Accessed 11 March 2019.

  45. 45.

    Spector-Bagdady K, Pike E. Consuming genomics: regulating direct-to-consumer genetic and genomic information. Nebraska Law Rev. 2014;92:677–745.

  46. 46.

    Green RC, Farahany NA. The FDA is overcautious on consumer genomics. Nature. 2014;505:286–287.

  47. 47.

    Evans BJ. The limits of FDA’s authority to regulate clinical research involving high-throughput DNA sequencing. Food Drug Law J. 2015;70:259–287.

  48. 48.

    Code Fed Regulations. 2019; title 45, §164.104.

  49. 49.

    Code Fed Regulations. 2019; title 45, §164.500.

  50. 50.

    Code Fed Regulations. 2019; title 45, §160.103.

  51. 51.

    Federal policy for the protection of human subjects. Fed Regist. 2017;82:7149–7274.

  52. 52.

    Code Fed Regulations. 2019; title 45, §164.514.

  53. 53.

    Fader ED, Christoforou M. Health care privacy and the Health Insurance Portability and Accountability Act of 1996. In: Weikers RN, Costello M, editors. Data security and privacy law. Eagan, MN: Thomson Reuters; 2019: ch. 12.

  54. 54.

    Prince AER. Comprehensive protection of genetic information: one size privacy or property models may not fit all. Brooklyn Law Rev. 2013;79:175–227.

  55. 55.

    US Code. 2019; title 15, chapter 2, subchapter I.

  56. 56.

    US Code. 2019; title 15, §45.

  57. 57.

    FTC v. Wyndham Worldwide Corp. 3d Cir. 2015; 799 F.3d 236.

  58. 58.

    Pom Wonderful LLC v. FTC. DC Cir. 2015; 777 F.3d 478.

  59. 59.

    Wagner JK. FTC takes action to protect consumers from false genetic advertising claims. The Privacy Report. 3 July 2014. https://theprivacyreport.com/2014/07/03/ftc-takes-action-to-protect-consumers-from-false-genetic-advertising-claims/. Accessed 17 March 2019.

  60. 60.

    US Code. 2019; title 15, §44.

  61. 61.

    US Code. 2019; title 15, chapter 91.

  62. 62.

    Health Information Technology for Economic and Clinical Health Act. Public Law No. 111-5, title XIII. 2009.

  63. 63.

    US Federal Trade Commission (FTC). At-home genetic tests: a healthy dose of skepticism may be the best prescription. 2006. https://osp.od.nih.gov/wp-content/uploads/2013/11/DTC_Consumer_Alert_Jul06.pdf. Accessed 5 June 2019.

  64. 64.

    In the matter of GeneLink, Inc. Decision and order. FTC 2014. Docket no. C-4456.

  65. 65.

    In the matter of foru™ International Corp. Decision and order. FTC 2014. Docket no. C-4457.

  66. 66.

    In the matter of L’Oréal USA, Inc. Agreement containing consent order. FTC 2014. File no. 1223016.

  67. 67.

    Senator Charles Schumer (D-NY) letter to the FTC regarding personal genomics. 2017. https://www.schumer.senate.gov/newsroom/press-releases/schumer-reveals-popular-at-home-dna-test-kits-are-putting-consumer-privacy-at-great-risk-as-dna-firms-could-sell-your-most-personal-info-and-genetic-data-to-all-comers-senator-pushes-feds-to-investigate_ensure-fair-privacy-standards-for-all-dna-kits. Accessed 17 March 2019.

  68. 68.

    Baram M. The FTC is investigating DNA firms like 23andMe and Ancestry over privacy. Fast Company. 2018. https://www.fastcompany.com/40580364/the-ftc-is-investigating-dna-firms-like-23andme-and-ancestry-over-privacy. Accessed 11 March 2019.

  69. 69.

    FTC. Mobile health apps interactive tool. 2016. https://www.ftc.gov/tips-advice/business-center/guidance/mobile-health-apps-interactive-tool. Accessed 17 March 2019.

Download references

Acknowledgements

The authors wish to thank Meredith Trejo and Isabel Canfield for their research assistance.

Author information

Correspondence to Christi J. Guerrini JD, MPH.

Ethics declarations

Disclosure

G.H.J. discloses that Epstein Becker Green might now or in the future provide legal or regulatory advice to entities that operate as or are affiliated with third-party genetic interpretation services. A.L.M. discloses that she was a member of the committee of the US National Academies of Sciences, Engineering, and Medicine that produced the report, Returning Individual Research Results to Participants: Guidance for a New Research Paradigm. C.J.G. was a consultant to the committee. The other authors declare no conflicts of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guerrini, C.J., Wagner, J.K., Nelson, S.C. et al. Who’s on third? Regulation of third-party genetic interpretation services. Genet Med (2019) doi:10.1038/s41436-019-0627-6

Download citation

Keywords

  • direct-to-consumer screening and testing
  • genetic services
  • genetic privacy
  • health policy
  • ELSI

Further reading